Dyadic International (DYAI) Net Cash Flow (2018 - 2026)
Dyadic International (DYAI) posted Net Cash Flow of -$697138.0 for Q1 2026, up 46.45% sequentially from -$1.3 million in Q4 2025, and up 51.7% YoY from -$459547.6 in Q1 2025.
Dyadic International (DYAI) Net Cash Flow (2018 - 2026) Analysis & Trends
Dyadic International has reported Net Cash Flow for 9 years, with the latest figure at -$697138.0 in Q1 2026.
- Quarterly Net Cash Flow rose 51.7% year-over-year to -$697138.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91048.0 (up 101.65% YoY) and the FY2025 annual result came in at -$655192.0, down 26297.74% from the prior year.
- Net Cash Flow advanced to -$697138.0 in Q1 2026 per DYAI's latest filing, from -$1.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $4.1 million in Q1 2024 and troughed at -$4.4 million in Q2 2024.
- A 5-year average of -$620066.8 and a median of -$889226.0 in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow plunged 731.53% in 2024, then soared 1593.55% in 2025.
- Over 5 years, Net Cash Flow stood at -$922344.0 in 2022, then advanced by 3.59% to -$889226.0 in 2023, then soared by 166.48% to $591131.0 in 2024, then sank by 320.25% to -$1.3 million in 2025, then soared by 46.45% to -$697138.0 in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$697138.0, -$1.3 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | -697,138.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -697,138.00 |
| Mar 31, 2026 | -697,138.00 |
| Dec 31, 2025 | -1.30 Mn |
| Dec 31, 2025 | -1.30 Mn |
| Sep 30, 2025 | 3.18 Mn |
| Sep 30, 2025 | 3.18 Mn |
| Jun 30, 2025 | -1.09 Mn |
| Jun 30, 2025 | -1.09 Mn |
| Mar 31, 2025 | -1.44 Mn |
| Mar 31, 2025 | -1.44 Mn |
| Dec 31, 2024 | 591,131.00 |
| Dec 31, 2024 | 591,131.00 |
| Sep 30, 2024 | -213,034.00 |
| Sep 30, 2024 | -213,034.00 |
| Jun 30, 2024 | -4.44 Mn |
| Jun 30, 2024 | -4.44 Mn |
| Mar 31, 2024 | 4.06 Mn |
| Mar 31, 2024 | 4.06 Mn |
| Dec 31, 2023 | -889,226.00 |
| Dec 31, 2023 | -889,226.00 |